U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07525960) titled 'A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body' on April 06.
Brief Summary: The primary purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NDI-5001 administered as a capsule following daily oral dosing in adult males with X-linked congenital nephrogenic diabetes insipidus (NDI) due to vasopressin receptor Type 2 (V2R) mutations.
Study Start Date: June 02
Study Type: INTERVENTIONAL
Condition:
X-linked Congenital Nephr...